Inhibikase Therapeutics (IKT) Capital Leases (2022 - 2024)
Historic Capital Leases for Inhibikase Therapeutics (IKT) over the last 3 years, with Q1 2024 value amounting to $58330.0.
- Inhibikase Therapeutics' Capital Leases fell 6725.06% to $58330.0 in Q1 2024 from the same period last year, while for Mar 2024 it was $58330.0, marking a year-over-year decrease of 6725.06%. This contributed to the annual value of $90124.0 for FY2023, which is 5613.36% down from last year.
- According to the latest figures from Q1 2024, Inhibikase Therapeutics' Capital Leases is $58330.0, which was down 6725.06% from $90124.0 recorded in Q4 2023.
- Inhibikase Therapeutics' 5-year Capital Leases high stood at $232020.0 for Q3 2022, and its period low was $58330.0 during Q1 2024.
- Moreover, its 3-year median value for Capital Leases was $149971.0 (2023), whereas its average is $147859.9.
- In the last 5 years, Inhibikase Therapeutics' Capital Leases tumbled by 4784.37% in 2023 and then crashed by 6725.06% in 2024.
- Over the past 3 years, Inhibikase Therapeutics' Capital Leases (Quarter) stood at $205451.0 in 2022, then plummeted by 56.13% to $90124.0 in 2023, then crashed by 35.28% to $58330.0 in 2024.
- Its Capital Leases was $58330.0 in Q1 2024, compared to $90124.0 in Q4 2023 and $121013.0 in Q3 2023.